English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/143130
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Prognostic relevance of estrogen receptor-alpha Ser167 phosphorylation in stage II-III colon cancer patients

AuthorsLópez-Calderero, Iker; Carnero, Amancio ; Astudillo, Aurora; Palacios Calvo, José ; Chaves-Conde, Manuel; Benavent, Marta; Limón, María L.; García-Carbonero, Rocío
KeywordsColon cancer
Prognosis
Immunohistochemistry
Estrogen receptor
Survival
Biomarkers
Tissue microarray
Issue DateDec-2014
PublisherElsevier
CitationHuman Pathology 45(12): 2437–2446 (2014)
AbstractPreclinical and clinical data suggest a protective role for estrogens on colon cancer (CRC) risk. estrogen receptor (ER) β is the prevalent ER in normal colonic mucosa, whereas its expression is significantly reduced in CRC. An increased ERα/β ratio has been documented in colon carcinomas and is associated with increased proliferation and decreased apoptosis. The aim of our study was to evaluate the expression of activated ERα and its prognostic implications in patients with stage II-III CRC. Phospho-ERαSer167 (pERαSer167) expression was assessed by immunohistochemistry in 218 CRC paraffin-embedded tumor samples. A high pERαSer167 expression was more commonly observed in women, older patients, and patients with high baseline glucose levels. This higher pERαSer167 expression was associated with decreased 5-year disease-free interval (DFI; 66% versus 78%, P = .07) and overall survival (65% versus 73%, P = .46). The negative impact of high pERαSer167 expression on DFI was particularly significant (P < .05) in women (85% versus 60%), young (82% versus 61%), nondiabetic (85% versus 66%), and stage II patients (86% versus 72% and low versus high pERαSer167, respectively). Multivariate analysis confirmed that pERαSer167 score was a significant prognostic factor for both DFI and overall survival, independent of sex, age, glucose levels, tumor stage, bowel obstruction/perforation, or adjuvant chemotherapy. These findings illustrate the relevance of estrogen pathways in colon cancer biology and may provide novel therapeutic avenues to be explored in this context.
Publisher version (URL)http://doi.org/10.1016/j.humpath.2014.08.008
URIhttp://hdl.handle.net/10261/143130
DOI10.1016/j.humpath.2014.08.008
Identifiersissn: 0046-8177
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.